Research article Special Issues

Simulation of carbon peaking process of high energy consuming manufacturing industry in Shaanxi Province: A hybrid model based on LMDI and TentSSA-ENN

  • To achieve the goals of carbon peaking and carbon neutrality in Shaanxi, the high energy consuming manufacturing industry (HMI), as an important contributor, is a key link and important channel for energy conservation. In this paper, the logarithmic mean Divisia index (LMDI) method is applied to determine the driving factors of carbon emissions from the aspects of economy, energy and society, and the contribution of these factors was analyzed. Meanwhile, the improved sparrow search algorithm is used to optimize Elman neural network (ENN) to construct a new hybrid prediction model. Finally, three different development scenarios are designed using scenario analysis method to explore the potential of HMI in Shaanxi Province to achieve carbon peak in the future. The results show that: (1) The biggest promoting factor is industrial structure, and the biggest inhibiting factor is energy intensity among the drivers of carbon emissions, which are analyzed effectively in HMI using the LMDI method. (2) Compared with other neural network models, the proposed hybrid prediction model has higher accuracy and better stability in predicting industrial carbon emissions, it is more suitable for simulating the carbon peaking process of HMI. (3) Only in the coordinated development scenario, the HMI in Shaanxi is likely to achieve the carbon peak in 2030, and the carbon emission curve of the other two scenarios has not reached the peak. Then, according to the results of scenario analysis, specific and evaluable suggestions on carbon emission reduction for HMI in Shaanxi are put forward, such as optimizing energy and industrial structure and making full use of innovative resources of Shaanxi characteristic units.

    Citation: Ke Hou, Jianping Sun, Minggao Dong, He Zhang, Qingqing Li. Simulation of carbon peaking process of high energy consuming manufacturing industry in Shaanxi Province: A hybrid model based on LMDI and TentSSA-ENN[J]. Mathematical Biosciences and Engineering, 2023, 20(10): 18445-18467. doi: 10.3934/mbe.2023819

    Related Papers:

    [1] Bing Xue, Jiakang Du, Hongchun Sun, Yiju Wang . A linearly convergent proximal ADMM with new iterative format for BPDN in compressed sensing problem. AIMS Mathematics, 2022, 7(6): 10513-10533. doi: 10.3934/math.2022586
    [2] Regina S. Burachik, Bethany I. Caldwell, C. Yalçın Kaya . Douglas–Rachford algorithm for control- and state-constrained optimal control problems. AIMS Mathematics, 2024, 9(6): 13874-13893. doi: 10.3934/math.2024675
    [3] Liping Geng, Jinchuan Zhou, Zhongfeng Sun, Jingyong Tang . Compressive hard thresholding pursuit algorithm for sparse signal recovery. AIMS Mathematics, 2022, 7(9): 16811-16831. doi: 10.3934/math.2022923
    [4] Wenxue Sun, Huiyuan Zhao, Xiao Zhang, Yuchao Sun, Xiaoxin Liu, Xueling Lv, Di Fan . Zero-watermarking Algorithm for Audio and Video Matching Verification. AIMS Mathematics, 2022, 7(5): 8390-8407. doi: 10.3934/math.2022468
    [5] Min Wang, Jiao Teng, Lei Wang, Junmei Wu . Application of ADMM to robust model predictive control problems for the turbofan aero-engine with external disturbances. AIMS Mathematics, 2022, 7(6): 10759-10777. doi: 10.3934/math.2022601
    [6] Siting Yu, Jingjing Peng, Zengao Tang, Zhenyun Peng . Iterative methods to solve the constrained Sylvester equation. AIMS Mathematics, 2023, 8(9): 21531-21553. doi: 10.3934/math.20231097
    [7] Nipa Jun-on, Raweerote Suparatulatorn, Mohamed Gamal, Watcharaporn Cholamjiak . An inertial parallel algorithm for a finite family of G-nonexpansive mappings applied to signal recovery. AIMS Mathematics, 2022, 7(2): 1775-1790. doi: 10.3934/math.2022102
    [8] Aliyu Muhammed Awwal, Poom Kumam, Kanokwan Sitthithakerngkiet, Abubakar Muhammad Bakoji, Abubakar S. Halilu, Ibrahim M. Sulaiman . Derivative-free method based on DFP updating formula for solving convex constrained nonlinear monotone equations and application. AIMS Mathematics, 2021, 6(8): 8792-8814. doi: 10.3934/math.2021510
    [9] Yue Zhao, Meixia Li, Xiaowei Pan, Jingjing Tan . Partial symmetric regularized alternating direction method of multipliers for non-convex split feasibility problems. AIMS Mathematics, 2025, 10(2): 3041-3061. doi: 10.3934/math.2025142
    [10] Jun Yang, Prasit Cholamjiak, Pongsakorn Sunthrayuth . Modified Tseng's splitting algorithms for the sum of two monotone operators in Banach spaces. AIMS Mathematics, 2021, 6(5): 4873-4900. doi: 10.3934/math.2021286
  • To achieve the goals of carbon peaking and carbon neutrality in Shaanxi, the high energy consuming manufacturing industry (HMI), as an important contributor, is a key link and important channel for energy conservation. In this paper, the logarithmic mean Divisia index (LMDI) method is applied to determine the driving factors of carbon emissions from the aspects of economy, energy and society, and the contribution of these factors was analyzed. Meanwhile, the improved sparrow search algorithm is used to optimize Elman neural network (ENN) to construct a new hybrid prediction model. Finally, three different development scenarios are designed using scenario analysis method to explore the potential of HMI in Shaanxi Province to achieve carbon peak in the future. The results show that: (1) The biggest promoting factor is industrial structure, and the biggest inhibiting factor is energy intensity among the drivers of carbon emissions, which are analyzed effectively in HMI using the LMDI method. (2) Compared with other neural network models, the proposed hybrid prediction model has higher accuracy and better stability in predicting industrial carbon emissions, it is more suitable for simulating the carbon peaking process of HMI. (3) Only in the coordinated development scenario, the HMI in Shaanxi is likely to achieve the carbon peak in 2030, and the carbon emission curve of the other two scenarios has not reached the peak. Then, according to the results of scenario analysis, specific and evaluable suggestions on carbon emission reduction for HMI in Shaanxi are put forward, such as optimizing energy and industrial structure and making full use of innovative resources of Shaanxi characteristic units.



    Infectious disease, in recent times, is a great concern in public health. Around the world, microbial infection causes mortality in millions of people every year [1][4]. Further, the microbes can turn resistant to antibiotics due to their high mutative capacity and morphological changes [5][7]. A nanoparticle (NP)-based treatment approach could be promising to overcome the drug-resistant effects of the microbes. Further, NPs can have innate antimicrobial activities [8],[9]. NPs can generate reactive oxygen species (ROS), which can damage DNA and proteins and block the growth of bacteria, fungi and viruses. Antibiotics conjugated with nanoparticles have therefore been thought to be an efficient antimicrobial regimen [10]. The antibiotic cefaclor attached to gold nanoparticles (52–22 nm) showed significant antibacterial activity [11],[12]. Biogenic selenium nanoparticles have anti-biofilm activity and effectively retard the growth of Pseudomonas aeruginosa, a Gram-negative bacteria [13],[14]. Similarly, TiO2 nanoparticles have been found to inhibit the formation of fungal biofilms [15].

    Nanotechnology can help the world's medical community to fight against virus infection also [16],[17]. For example, studies have been done successfully on the effects of nano-materials as antivirals against the virus SARS-CoV-2, inhibiting its entry into cells, its RNA replication and, finally, its release [18][20]. In addition, nano-materials provide a wide range of opportunities for diagnosis, treatment and in controlling the biofilm formation. Recent advances of applications of various nanomaterials in the diagnosis and treatments of microbial infections have been reviewed elsewhere [21][24]. However, their impact on human tissues and the environment should be assessed before implementations in large-scale industry are carried out [25].

    Here, we discuss several aspects of using nanoparticles in infectious diseases, their pros and cons, challenges for nanoparticles and future prospects.

    Nanoparticles (NPs) belong to a group of substances having diameters ranging from 1–100 nm [26][29], and they possess the ability to penetrate the bacterial cell wall, which is made up of peptidoglycan. NPs can dismantle the peptidoglycan layer from Gram-positive bacteria and also overcome antimicrobial resistance [5],[30],[31],

    Table 1.  Antiviral nanoparticles and antibacterial activities.
    Antibacterial Nanoparticles Functions
    Gentamicin coated phosphatidylcholine–chitosan hybrid nanoparticles [32] Inhibit the growth of Gram-positive and Gram-negative bacteria [32]
    Supramolecular polyelectrolyte complexes, (like NH3+ of the β-cyclodextrin-chitosan complexes with the negatively-charged SO3 groups) [33]. Silver sulfadiazine molecules complexed with β-cyclodextrin releases silver ions which damages the bacterial cell wall [33]
    Vancomycin antibiotic encapsulated in polymersomes [34] Antibacterial effects against methicillin-resistant S. aureus [34]
    Mannose-chitosan complex nanoparticles [35] Mannose-chitosan complex nanoparticles have antibacterial activities against gram-positive and gram-negative bacteria [35]
    Teicoplanin-containing polylactic-co-glycolic acid (PLGA) nanoparticles [36] Showed an antibacterial effect on S. aureus [36]
    Pistacia lentiscus L. var. chia essential oil can be encapsulated within PLA nanoparticles [37] Showed an inhibitory effect on gram-positive and gram-negative bacteria [37]
    Silver nanoparticles with PLA nanocoatings and with polyethylene terephthalate nanofibers [38] Works against gram-positive and gram-negative bacteria, both [38]

     | Show Table
    DownLoad: CSV

    Viruses can infect prokaryotes as well as eukaryotes. Vaccines are effective in some of viral diseases such as smallpox, polio, etc, yet further opportunities to overcome antiviral drug resistance is possible by using NPs [39],[40].

    Table 2.  Antiviral nanoparticles and their functions.
    Antiviral Nanoparticles Functions
    Chitosan nanoparticles complex with peptides derived from HIV-1 P24 protein [41]. Showed reduced toxicity and sustained peptide drug release [41].
    NPs attached with hydroxypropyl-β-cyclodextrin and loaded with Dolutegravir [42]. Results in improved permeation of the drug through nasal mucosa without damaging the mucosa [42].

     | Show Table
    DownLoad: CSV
    Table 3.  Antifungal nanoparticles and their functions.
    Antifungal Nanoparticles Functions
    Administration of miconazole and farnesol together with chitosan NPs [43] The minimum inhibitory concentration (MIC) of nanosystems against C. albicans is similar to the values for the miconazole free drug [43]
    Chitosan nanoparticles incorporating itraconazole [44] Potentially inhibits the growth of C. neoformans, C. albicans and A. fumigatus [44]
    Nanocapsules containing modified polysaccharide for the delivery of amphotericin B [45] This nanosystem showed significant antifungal activity against C. albicans strains, compared to the free drug [45]

     | Show Table
    DownLoad: CSV
    Table 4.  Antiparasitic nanoparticles and their functions.
    Antiparasitic Nanoparticles Functions
    A poorly water-soluble compound, Triclabendazole, encapsulated within chitosan [46][49] Found successful in treatment of fascioliasis [46]
    Showed an inhibitory effect on Leishmania promastigotes protozoan parasites [47]

     | Show Table
    DownLoad: CSV

    Some industrial and biomedical applications of nano-materials as alternatives to commercially available antibiotics and anti-fungal medications are reviewed in [22],[24] (Tables 5 and 6).

    Table 5.  Nanomaterials with antifungal activities.
    Targets Antifungal activity Nanoparticle type Route of administration References
    Trichophyton rubrum AmB, CLT SLN, SLN Topical [50],[51]
    Candida albicans CLT, ECN, MN SLN-based stearate, SLN, SLN Topical [52][54]
    Candida species MN SLN-bearing Hydrogel, SLN Topical, Oro mucosal [55],[56]
    Aspergillus flavus ITZ; VRZ SLN Ocular [57],[58]
    Candida glabrata VRZ SLN Ocular [59]
    Candida species FLZ SLN Topical [60]
    Dermatophyte GF SLN N/A [61]
    Candida tropicalis AmB Ag N/A [62]
    Aspergillus niger AmB Ag N/A [63]
    Fusarium culmorum AmB Ag N/A [63]
    Aspergillus brasiliensis NYS, FLZ Ag N/A [64]
    Malassezia furfur KTZ Ag Topical [65]
    Paracoccidioides brasiliensis AmB PLGA N/A [66]
    Candida parapsilosis AmB CS-coated PCL Oral [67]
    Aspergillus fumigatus AmB L/CS N/A [68]

     | Show Table
    DownLoad: CSV
    Table 6.  Nanomaterials with antibacterial activities.
    Biomaterials Potential applications Bacteria Reference
    Cotton/silk fabrics containing reduced graphene oxide (RGO) and Ag/Cu NPs Antimicrobial protective medical textiles P. aeruginosa
    E. coli
    S. aureus
    [69]
    Polyvinyl alcohol containing Ag/Cu NPs Antibacterial contact lenses S. aureus
    P. aeruginosa
    [70]
    Lysozyme-coated Au NPs in combination with β-lactam Diabetic wound healing S. aureus
    Acinetobacter calcoaceticus
    P. aeruginosa
    E. coli
    Klebsiella pneumonia
    Bacillus subtilis, B. cereus
    [71]
    Keratin containing Ag NPs Skin wound healing and tissue recovery E. coli
    S. aureus
    [72]
    Ag NPs-loaded bacterial cellulose hydrogels Moist wound-healing hydrogels S. aureus
    P. aeruginosa
    [73]

     | Show Table
    DownLoad: CSV

    When NPs come into contact with blood, they may initiate some biological effects, which could be good or bad. Hence, it is important to determine the blood-NPs compatibility before they can be used in humans [74],[75]. A few observations are the following:

    • The blood-NPs compatibility depends on the size, structure and formulation of the NPs [74],[76].
    • Biopolymeric NPs have been found compatible when used in the treatment of asthma, tuberculosis and lung cancer [77],[78].

    Table 7.  Comparative biocompatibilities of several NPs.
    NPs In vitro and in vivo toxicity
    Dendrimers No toxic effects [79]
    Au NPs No toxic effects [80]
    Carbon nanotubes No toxic effects [81]
    Superparamagnetic Fe3O4 nanoparticles (SPIONs) No toxic effects [82]
    Silica-based NPs Si NPs cause toxicity to immune cells and tissues. The main mechanisms were pro-inflammatory responses, oxidative stress autophagy and so on. Surface and shape modifications may mitigate the toxicity effects of Si NPs, providing a new way to produce these NMs with less toxic impact [83],[84].
    Ag NPs
    • Induce cell shrinkage, apoptosis [85],[86]
    • Release free radicals and cause DNA damage [87]
    • Immunotoxicity in rats [88],[89]
    • Ag NP-biopolymer showed anti-bacterial activity but no toxic effects on mouse fibroblasts (NIH-3T3), human osteosarcoma cells (MG63) or human hepatocarcinoma cells (HepG2) [90],[91]
    Fe3O4-Au NPs No toxicity was observed in any cell types in culture [92]
    Manganese ferrite (MnFe2O4) NPs Showed biocompatibility at 125 µg/mL or below in 4T1 cells (a murine breast cancer cell line) [93]
    Ferrite NPs (Fe3O4, ZnFe3O4 and NiFe3O4) Showed toxicity against HeLa cell lines at and above 100 µg/mL dosage [94]
    TiO2 NPs These NPs are non-toxic (at <l00 µg/mL) to humans [95]
    CaFe2O4 NPs Showed toxicity in humans at >250 µg/mL concentration [96]

     | Show Table
    DownLoad: CSV

    Since the accumulation of nanoparticles in the spleen and liver may turn out as toxic, biodegradable NPs (BNPs) should be more appropriate than non-degradable NPs [97]. Other significant factors are the following:

    • Nanopolymers are biodegradable and can encapsulate other therapeutic regimens to deliver them to the action site [98].
    • Polysaccharides, proteins and some synthetic polymers are the main sources of BNPs.
    • Polymersomes (or polymer vesicles) can be used for drug delivery as their coronas and membranes can be modified for biomedical active different groups. Polymersomes are very suitable drug deliver agent for bacterial infection, and cancer therapy, as well.
    • Antibacterial polymersomes are divided into three categories:
      • polymersomes as antibiotic nanocarriers,
      • intrinsically antibacterial polymersomes and
      • antibacterial polymersomes with supplementary means, including photothermal and photodynamic therapy.
    • Similarly, the anticancer polymersomes are divided into two categories:
      • Polymersome-based delivery systems, and
      • Anticancer polymersomes with supplementary means.

    In this review, the prospective antibacterial and anticancer polymersomes are discussed.

    The end application is the main criterion for the selection of the polymer, but their size, bio-compatibility, biodegradability and the capability of encapsulation of the drug materials are similarly important factors to be considered [99]. Some of the different biodegradable polymers and their merits for use as BNPs are listed in Table 8.

    Table 8.  Some polymers for the synthesis of BNPs.
    Poly lactic-co-glycolic acid (PLGA)
    • Produce biodegradable products, lactic and glycolic acids [100]
    • Generally used in the production of nanovaccines, gene delivery and also the production of protein/peptide-based nanomedicines [100],[101]
    Poly lactic acid (PLA)
    • PLA is biocompatible and biodegradable, breaking down to lactic acid in the body [102]
    Gelatin
    • Gelatin is a polyampholyte and is used in food products and also in medicine [103]
    Polycyclic aromatic compounds (PACs)
    • Upon biodegradation, PACs produce compounds toxic to the central nervous system [104]

     | Show Table
    DownLoad: CSV

    NPs may be considered by the human body as a foreign particle, so macrophages / phagocytic cells can remove them from blood circulation. Therefore, the surfaces of NPs should be modified to allow them to bypass the immune system of the body [105], so they can stay in the vascular system for a longer period of time and may reach their target safely [106]. PEGylation of NPs results in less interaction with phagocytes and being sustained longer in the circulation system [107]. Similarly, tocopherol PEG-1000 succinate can modify NPs, which then in turn exhibit increased adhesion towards tumor cell surfaces [108],[109].

    The conventional methods of drug delivery have several limitations, such as poor biodistribution, lack of selectivity and limited effectiveness [110],[111]. Attachment of NPs to the therapeutic drug can make possible site-specific delivery and can reduce any undesirable side effects [112],[113]. Representative clinical trials with small molecule-based targeting have been tabulated elsewhere [114],[115].

    The use of nanotechnology in medicine is mostly for targeted drug delivery and also to reduce toxicity and side effects of the drugs. Until recently, it was not realized that these carrier systems themselves may cause risks to the patient. Therefore, a conceptual understanding of biological responses to nanomaterials is needed to develop [116][123].

    • The major concern is to maintain the proper size and shape of mono-dispersed NPs with stability during synthesis [124].
    • NPs may accumulate in different bio-organs, which may cause problems in normal biological function in the future [125].
    • Since NPs may escape the immune challenge of the body, they may cause some sort of inflammation or toxicity [126].
    • NPs can generate ROS, which are major contributors of inflammation, oxidative stress and apoptosis [127].
    • Still, there are many other disadvantages in using NPs. For example, toxicity, environmental harm and organ damage may be caused by nanoparticles [128].
    • Nanoparticles, after a threshold limit, may be toxic in nature and have to be degraded chemically.
    • Some identified toxic mechanisms are through the production of ROS, which is cytotoxic, genotoxic, and neurotoxic, also. Those toxic effects of nanoparticles' depends on its type, size, surface area, shape, aspect ratio, surface coating, crystallinity, dissolution and agglomeration properties. Therefore, it is important to consider of any toxic effects of nanoparticles when it is being synthesized [129],[130].

    It has already been demonstrated that many nanoparticles in lab rats have resulted in lung inflammation and blood clotting, and in the human body they could trigger unwanted reactions like damage to cells and organs [131].

    • Nanoparticles produce ROS and oxidative stress, which may cause neurodegenerative diseases such as Alzheimer's and Parkinson's diseases [132].
    • Uptake of the nanoparticles through the olfactory epithelium can also take place, leading to epithelial cell injury, which can compromise the basic functions of the nose [133].
    • Silica exposure causes oxidative stress. At high doses, silica induces membrane damage and cytotoxicity [134].
    • Another limitation of using nanotechnology in medicine is its high expense. The use of nanomedicine would increase the cost of health care, which would make its access difficult for the poor [135]. Furthermore, the ethical, social and legal facets of nanomedicine need to be handled tactfully to gain civic backing. Though efforts are being made to increase the understanding of using nanomedicine in living beings, there is still ambiguity surrounding the risks that humans would be exposed to with its use. As a result, the clinical trials involving nanomedicine pose distinctive challenges. The leading ethical issues encompass assessing, managing and communicating the risk during clinical trials. To evade the possibility of public criticism, it becomes imperative to educate the people about the benefits and pitfalls of nanomedicine [136].

    A new antiviral regimen could emerge as an antimicrobial. NV-387 is a self-assembling, uniform and tailorable linear homopolymer designed and designated as a TheraCour platform polymer. Here, the monomer is functionalized by attaching polyethylene glycol (PEG) connected covalently with a site-targeting ligand [137] (Figure 1).

    Figure 1.  Schematic design of TheraCour NV-387 biopolymer.

    This binding results in avidity and that force leads to passive fusion of the virus. Further, being encapsulated, the loaded drug can be released from the polymer backbone in a covalent system immediately [19],[138],[139], TheraCour platform polymer (NV-387) adds further advantages providing an extreme level of tailorability, also:

    (A) Different ligands can be chosen for different targets.

    (B) By changing the appropriate lipid length and balancing the PEG-monomer chain length, one can balance the hydrophobic/hydrophilic balance of the PEG Polymer. The longer lipid chain would be more suitable for dermal delivery of the drug as a cream or ointment. In contrast, short lipid chains would result more hydrophilic in nature and merely assist in conformational stability and adherence to the cell membrane.

    (C) The rate of release of the API can be modified by tailoring the connector, like pH-sensing, or esterase or protease-specific functions, etc.

    (D) The polymerization can be controlled within the limits (Flory equation), to provide a desirable clearance characteristics.

    NV-387 is a non-crystalline semi-solid, off-white, waxy in texture material (at room temperature). It's theoretical molecular formula is C104H188N2O44S4. The calculated formula weight of the polymer repeat unit (RU) is 2298.85 g/mol. The degree of polymerization, “n”, in P10M2DT (HDA)x (MMSA)y polymer is 8 ± 2 [19]. Pharmaceutical properties, formulations for injection, physical properties, and chemical properties are all available elsewhere [19].

    NV-387 is a non-crystalline semi-solid, off-white, waxy in texture material (at room temperature). It's theoretical molecular formula is C104H188N2O44S4. The calculated formula weight of the polymer repeat unit (RU) is 2298.85 g/mol. The degree of polymerization, “n”, in P10M2DT (HDA)x (MMSA)y polymer is 8 ± 2 [19].

    Pharmaceutical properties, formulations for injection, physical properties, and chemical properties are all available elsewhere [19].

    These materials have been shown to be capable of (a) site-directed (address-based) cell or virus targeting, (b) protective active pharmaceutical ingredient (API) encapsulation, (c) direct delivery of such encapsulated APIs into the address-specified cell or virus, (d) tailorable circulation lifetime and (e) sustained delivery characteristics, while at the same time being biocompatibility, non-toxic, non-immunogenic, and biodegradable [137].

    In viral diseases, TheraCour platform based nanopolymer, NV-387, is noticeable. The therapeutic principle of NV-387 is based on its unique structure. As we know that the virus envelope carry a lipid membrane derived from the host cell membrane, the TheraCour polymer can attack viruses. Interestingly, no active API is required in this scenario if the ligand is properly chosen for making the biopolymer. Once the virus is attached by the micelle carrying ligands, lipid-lipid mixing essentially pulls the lipid membrane of the virus to the site of the attack and the virus gets dispersed, resulting a naked virus capsid that cannot infect cells (Figure 2) [139][143].

    Figure 2.  TheraCour Platform Technology based Nanoviricide is a Cell Mimic. A nanoviricide “looks like” a human cell to the virus. A nanoviricide micelle encapsulates the virus particle, even they mutate, and dismantle the virus structure. Step 1: A Nanoviricide™ binds to virus particle; Step 2: Lipid-Lipid fusion of Nanoviricide™ with virus particles; Step 3: Encapsulation of virus particle by Nanoviricide™; Step 4: Nanoviricide™ destroy the virus particle.

    This model is the most advanced in the antiviral field. In particular, a drug, targeting for SARS-CoV-2 virus, NV-CoV-2 has completed preclinical studies including GLP Safety/Toxicology and is expected to enter human clinical trials soon. Another derivative, NV-CoV-2-R that encapsulates remdesivir within the core of NV-CoV-2 has shown effectiveness significantly surpassing that of the standard remdesivir formulation, which correlates with significantly improved pharmacokinetics of remdesivir in vivo in animal model studies. Some uses of TheraCour polymer are the entire drug use chain are shown in Tables 9 and 10.

    Table 9.  TheraCour drug solves problems in the drug use chain.
    Vehicle Administer Blood Stream Specific Targeting Cell Membrane
    TheraCour Injection Encapsulated “Nano Velcro Snaking” Take API Across
    Liposomes Infusion Unstable Not Much Success Partial Effect
    Cremophore Infusion Unstable None Some Effect?
    Cydex Infusion Full Apart None None
    PEGylation Infusion Stable None None
    Polydrug Injection Stable None Depends
    Polypeptides Infusion Injection Stable None None
    Dendrimers Infusion Injection Toxic Hard Sphere Few Points May Take API Across

     | Show Table
    DownLoad: CSV
    Table 10.  TheraCour approach is a unique beneficiaL feature than other nanomedicine approaches.
    Vehicle TheraCour Dendrimer PLA/PLGA Virus Based Nanoshells, Metalics
    Nanoscale Velcro Effect with Wrap-On Yes No No No No
    Technology Complexity Simple Complex Medium Complex Complex
    Safety Safe No Medium No Medium
    Specific Targeting Yes: Flexible Wrap-ON Yes: Limited by Hard Bal No No May be
    Detection Yes Yes No No May be
    Extended Release Yes May be Yes Yes Accumulate
    Controlled Release Yes May be Yes No No
    Efficacy Improvements Yes, Very Large Yes No (Slow release only) Yes but infectious May be

     | Show Table
    DownLoad: CSV

    SARS-CoV-2 belongs to a β-family of human coronavirus, which causes the severe lower tract infectious disease called COVID-19 [144]. Throughout the world this pandemic disease virus once evolved in November 2019 is continuously mutating to a new form and infecting people till date. The newer variants (Omicron BA.2) possess greater transmissibility with R0 as 12 [145].

    The once effective drugs against SARS-CoV-2, like remdesivir (Gilead), molnupiravir (Merck), and Paxlovid™ (Pfizer) turnout with significant limitations in humans. Molnupiravir is reported as mutagenic and further has poor efficacy. Paxlovid is virostatic and the virus rebounds once the drug is withdrawn. Remdesivir is highly effective in vitro studies, however, in vivo, its efficacy is not satisfactory at all. This may be due to the instability of Remdesivir in the body circulation system [146],[147].

    NV-387 is highly effective in cell cultures against coronavirus hCoV-NL63 which like SARS-CoV-2, binds to the ACE2 cell receptor [140]. hCoV-229E that binds to a different cellular receptor, Aminopeptidase N (APN), also can be inhibited by NV-387, indicating itself as a broad-spectrum anti-coronavirus nanopolymer [20],[147],[148].

    The mechanism of nanoviricide's function is shown through electron photomicrographs (Figure 3). In this study, the murine cytomegalovirus (MCMV) was incubated with a nanoviricide containing sialic acid as a ligand. The light area at top right corner in Figure 3-II indicates that the lipid coat was deformed due to the binding of nanoviricide micelle in that area. The loss of the viral envelope results the lack of viral glycoproteins required for cellular entry and thus becomes non-infectious. Figure 3-III shows that only virion capsids remain as a result of the attack. We have demonstrated a convincing success of our drug NV-CoV-2-R which is an encapsulated remdesivir into the polymeric micelle (NV-CoV-2), in inhibiting the virus growth in animal models [139],[142].

    Figure 3.  Effects of Two Different Nanoviricides Binding to Murine Cytomegalo virus (MCMV). I: Control virion: MCMV containing multiple capsids and a lipid coat with coat proteins; II & III: MCMV virion treated with two different nanoviricides. Virion disruption with capsids spilling out.

    NV-387 is a TheraCour biopolymer (API) which on formulation was converted to a drug product against corona virus, and designated as NV-CoV-2. Safety studies on NV-387/NV-CoV-2 indicate that:

    • No abnormal respiratory function or in neurobehavioral aspects were notices in all doses of the test compounds was observed in a rat model.
    • No change in body temperature after the i.v. administration of NV-CoV-2 in rats.
    • Heart rate, blood pressure, cardiac rhythm, and ECG parameters of cynomolgus monkeys were noticed normal after i.v. administration of NV-CoV-2 in them [19].
    • Additionally, NV-387/NV-CoV-2, both were non-immunogenic, non-mutagenic, and non-genotoxic in a rat model.

    The use of nanomaterials has been increasing, with concerns about drug-nanomaterial stability, biocompatibility and biodegradability; and there is interest in control and tailored payload release of the drug, without any side effects, and improving patient compliance [149],[150]. With these concerns, recently, nucleic acid-based cross-linkers, as they are able to self-assemble into a stable 3-dimensional structures, have gained much attention [149][151]. In addition, nucleic acids can act as a targeting agent through engineered aptamer and drug payload carriers. They also have shown the ability to control the release of proteins [152][155]. Owing to these versatile characteristics, it is expected that nucleic acid-based hydrogels will be an important regimen in the future for targeted drug release.

    Treatment of infectious disease with antibiotics becomes a challenge when the organisms evolve drug resistance. Therefore, discovery of methods of treatment and/or therapeutic regimen warrants great priority. Nanotechnology offers an innovative advance in NP-based bio-imaging, which can be used for early detection, diagnosis and treatment of many diseases, especially those that are caused by drug-resistant microorganisms. Nanoparticles have been shown, due to their unique size, shape, charge and surface area, to possess unique activity against different microbial infections. In addition, NPs find their other uses in drug delivery, gene delivery and targeted therapy of various diseases including cancer.

    The development of nanotechnology for the synthesis of NPs/nanocomposites can be used to treat various diseases which are difficult to treat with the conventional approaches. However, the limitations and health risks that are associated with these nano-sized particles should not be ignored. Nowadays, in many cases, nanotherapy along with the conventional antibiotic therapy is used to overcome microbial resistance. NPs/nanocomposites may resolve difficulties in managing complicated diseases. However, safety and efficacy issues of NPs are now the main concern before their use in humans.



    [1] IPCC, Climate change 2022: Mitigation of climate change, 2022. Available from: https://www.ipcc.ch/report/sixth-assessment-report-working-group-3/
    [2] Xinhua News Agency, Strengthening Action to Address Climate Change: China's National Independent Contribution, 2015. Available from: http://www.gov.cn/xinwen/2015-06/30/content_2887330.htm
    [3] X. Xu, X. Gou, W. Zhang, Y. Zhao, Z. Xu, A bibliometric analysis of carbon neutrality: Research hotspots and future directions, Heliyon, 9 (2023). https://doi.org/10.1016/j.heliyon.2023.e18763 doi: 10.1016/j.heliyon.2023.e18763
    [4] Shaanxi Provincial Development and Reform Commission, Plan for energy conservation and carbon reduction in key areas of high energy consuming industries in Shaanxi Province, 2022. Available from: http://sndrc.Shaanxi.gov.cn/fgyw/tzgg/IjaAVv.htm
    [5] M. Z. Du, F. E. Wu, D. F. Ye, Y. T. Zhao, L. P. Liao, Exploring the effects of energy quota trading policy on carbon emission efficiency: Quasi-experimental evidence from China, Energy Econom., 124 (2023). https://doi.org/10.1016/j.eneco.2023.106791 doi: 10.1016/j.eneco.2023.106791
    [6] Y. Y. Guo, X. J. Gou, Z. S. Xu, M. Skare, Carbon pricing mechanism for the energy industry: A bibliometric study of optimal pricing policies, Acta Montan. Slovaca, 27 (2022), 49–69. https://doi.org/10.46544/AMS.v27i1.05 doi: 10.46544/AMS.v27i1.05
    [7] J. D. Rivera-Niquepa, D. Rojas-Lozano, P. M. De Oliveira-De Jesus, J. M. Yusta, Decomposition analysis of the Aggregate Carbon Intensity (ACI) of the power sector in Colombia-A multi-temporal analysis, Sustainability, 14 (2022). https://doi.org/10.3390/su142013634 doi: 10.3390/su142013634
    [8] Y. Wang, C. Zhang, A. T. Lu, L. Li, Y. M. He, J. J. ToJo, et al., A disaggregated analysis of the environmental Kuznets curve for industrial CO2 emissions in China, Appl. Energy, 190 (2017), 172–180. https://doi.org/10.1016/j.apenergy.2016.12.109 doi: 10.1016/j.apenergy.2016.12.109
    [9] Q. Perrier, C. Guivarch, O. Boucher, Diversity of greenhouse gas emission drivers across European countries since the 2008 crisis, Climate Policy, 19 (2019), 1067–1087. https://doi.org/10.1080/14693062.2019.1625744 doi: 10.1080/14693062.2019.1625744
    [10] D. Zhang, G. Liu, C. Chen, Y. Zhang, Y. Hao, M. Casazza, Medium-to-long-term coupled strategies for energy efficiency and greenhouse gas emissions reduction in Beijing (China), Energy Policy, 127 (2019), 350–360. https://doi.org/10.1016/j.enpol.2018.12.030 doi: 10.1016/j.enpol.2018.12.030
    [11] X. Zou, R. F. Wang, G. H. Hu, Z. Rong, J. X. Li, CO2 emissions forecast and emissions peak analysis in Shanxi Province, China: An application of the LEAP Model, Sustainability, 14 (2022). https://doi.org/10.3390/su14020637 doi: 10.3390/su14020637
    [12] H. T. Ma, W. Sun, S. J. Wang, L. Kang, Structural contribution and scenario simulation of highway passenger transit carbon emissions in the Beijing-Tianjin-Hebei metropolitan region, China, Resour. Conserv. Recycl., 140 (2019), 209–215. https://doi.org/10.1016/j.resconrec.2018.09.028 doi: 10.1016/j.resconrec.2018.09.028
    [13] H. B. Wang, B. W. Li, M. Q. Khan, Prediction of Shanghai electric power carbon emissions based on improved STIRPAT Model, Sustainability, 14 (2022). https://doi.org/10.3390/su142013068 doi: 10.3390/su142013068
    [14] C. B. Wu, G. H. Huang, B. G. Xin, J. K. Chen, Scenario analysis of carbon emissions' anti-driving effect on Qingdao's energy structure adjustment with an optimization model, Part I: Carbon emissions peak value prediction, J. Cleaner Product., 172 (2018), 466–474. https://doi.org/10.1016/j.jclepro.2017.10.216 doi: 10.1016/j.jclepro.2017.10.216
    [15] X. Q. Liu, Y. M. Ye, D. D. Ge, Z. Wang, B. Liu, Study on the evolution and trends of agricultural carbon emission intensity and agricultural economic development levels-evidence from Jiangxi Province, Sustainability, 14 (2022). https://doi.org/10.3390/su142114265 doi: 10.3390/su142114265
    [16] H. Wang, Z. Zhang, Forecasting Chinese provincial carbon emissions using a novel grey prediction model considering spatial correlation, Expert Syst. Appl., 209 (2022). https://doi.org/10.1016/j.eswa.2022.118261 doi: 10.1016/j.eswa.2022.118261
    [17] Y. S. Huang, L. Shen, H. Liu, Grey relational analysis, principal component analysis and forecasting of carbon emissions based on long short-term memory in China, J. Cleaner Product., 209 (2019), 415–423. https://doi.org/10.1016/j.jclepro.2018.10.128 doi: 10.1016/j.jclepro.2018.10.128
    [18] Z. Zuo, H. Guo, J. Cheng, An LSTM-STRIPAT model analysis of China's 2030 CO2 emissions peak, Carbon Manag., 11 (2020), 577–592. https://doi.org/10.1080/17583004.2020.1840869 doi: 10.1080/17583004.2020.1840869
    [19] S. AlKheder, A. Almusalam, Forecasting of carbon dioxide emissions from power plants in Kuwait using United States Environmental Protection Agency, Intergovernmental panel on climate change, and machine learning methods, Renewable Energy, 191 (2022), 819–827. https://doi.org/10.1016/j.renene.2022.04.023 doi: 10.1016/j.renene.2022.04.023
    [20] X. Y. Zhou, L. B. Bai, J. Y. Bai, Y. Y. Tian, W. Q. Li, Scenario prediction and critical factors of CO(2)emissions in the Pearl River Delta: A regional imbalanced development perspective, Urban Climate, 44 (2022). https://doi.org/10.1016/j.uclim.2022.101226 doi: 10.1016/j.uclim.2022.101226
    [21] S. Zhang, Z. Huo, C. Zhai, Building carbon emission scenario prediction using STIRPAT and GA-BP neural network model, Sustainability, 14 (2022). https://doi.org/10.3390/su14159369 doi: 10.3390/su14159369
    [22] W. B. Qiao, H. F. Lu, G. F. Zhou, M. Azimi, Q. Yang, W. C. Tian, A hybrid algorithm for carbon dioxide emissions forecasting based on improved lion swarm optimizer, J. Cleaner Product., 244 (2020). https://doi.org/10.1016/j.jclepro.2019.118612 doi: 10.1016/j.jclepro.2019.118612
    [23] F. Kong, J. B. Song, Z. Z. Yang, A novel short-term carbon emission prediction model based on secondary decomposition method and long short-term memory network, Environ. Sci. Pollut. Res., 29 (2022), 64983–64998. https://doi.org/10.1007/s11356-022-20393-w doi: 10.1007/s11356-022-20393-w
    [24] L. Shi, X. Ding, M. Li, Y. Liu, Research on the capability maturity evaluation of intelligent manufacturing based on firefly algorithm, sparrow search algorithm, and BP neural network, Complexity, 2021 (2021). https://doi.org/10.1155/2021/5554215 doi: 10.1155/2021/5554215
    [25] J. Li, W. Wang, G. Chen, Z. Han, Spatiotemporal assessment of landslide susceptibility in Southern Sichuan, China using SA-DBN, PSO-DBN and SSA-DBN models compared with DBN model, Adv. Space Res., 69 (2022), 3071–3087. https://doi.org/10.1016/j.asr.2022.01.043 doi: 10.1016/j.asr.2022.01.043
    [26] W. Guan, Y.-M. Zhu, J.-J. Bao, J. Zhang, Predicting buckling of carbon fiber composite cylindrical shells based on backpropagation neural network improved by sparrow search algorithm, J. Iron Steel Res. Int., (2023). https://doi.org/10.1007/s42243-023-00966-w doi: 10.1007/s42243-023-00966-w
    [27] J. Tang, R. Gong, H. Wang, Y. Liu, Scenario analysis of transportation carbon emissions in China based on machine learning and deep neural network models, Environ. Res. Letters, 18 (2023). https://doi.org/10.1088/1748-9326/acd468 doi: 10.1088/1748-9326/acd468
    [28] J. Hu, J. Bi, H. Liu, Y. Li, S. Ao, Z. Luo, Prediction of resistance spot welding quality based on BPNN optimized by improved sparrow search algorithm, Materials, 15 (2022). https://doi.org/10.3390/ma15207323 doi: 10.3390/ma15207323
    [29] C. Zhao, J. Ma, W. Jia, H. Wang, H. Tian, J. Wang, et al., An apple fungal infection detection model based on BPNN optimized by sparrow search algorithm, Biosensors-Basel, 12 (2022). https://doi.org/10.3390/bios12090692 doi: 10.3390/bios12090692
    [30] M. Yang, Y. S. Liu, Research on the potential for China to achieve carbon neutrality: A hybrid prediction model integrated with elman neural network and sparrow search algorithm, J. Environ. Manag., 329 (2023). https://doi.org/10.1016/j.jenvman.2022.117081 doi: 10.1016/j.jenvman.2022.117081
    [31] Y. Huang, H. Wang, H. Liu, S. Liu, Elman neural network optimized by firefly algorithm for forecasting China's carbon dioxide emissions, Syst. Sci. Control Eng., 7 (2019), 8–15. https://doi.org/10.1080/21642583.2019.1620655 doi: 10.1080/21642583.2019.1620655
    [32] L. G. B. Ruiz, R. Rueda, M. P. Cuellar, M. C. Pegalajar, Energy consumption forecasting based on Elman neural networks with evolutive optimization, Expert Syst. Appl., 92 (2018), 380–389. https://doi.org/10.1016/j.eswa.2017.09.059 doi: 10.1016/j.eswa.2017.09.059
    [33] G. Bedi, G. K. Venayagamoorthy, R. Singh, Development of an IoT-Driven building environment for prediction of electric energy consumption, IEEE Int. Things J., 7 (2020), 4912–4921. https://doi.org/10.1109/jiot.2020.2975847 doi: 10.1109/jiot.2020.2975847
    [34] Y. L. Wang, X. J. Chen, C. L. Li, Y. Yu, G. Zhou, C. Y. Wang, et al., Temperature prediction of lithium-ion battery based on artificial neural network model, Appl. Thermal Eng., 228 (2023). https://doi.org/10.1016/j.applthermaleng.2023.120482
    [35] M. Du, R. Feng, Z. Chen, Blue sky defense in low-carbon pilot cities: A spatial spillover perspective of carbon emission efficiency, Sci. Total Environ., 846 (2022). https://doi.org/10.1016/j.scitotenv.2022.157509
    [36] J. Xue, B. Shen, A novel swarm intelligence optimization approach: Sparrow search algorithm, Syst. Sci. Control Eng., 8 (2020), 22–34. https://doi.org/10.1080/21642583.2019.1708830 doi: 10.1080/21642583.2019.1708830
    [37] J. Feng, J. Zhang, X. Zhu, W. Lian, A novel chaos optimization algorithm, Multi. Tools Appl., 76 (2017), 17405–17436. https://doi.org/10.1007/s11042-016-3907-z doi: 10.1007/s11042-016-3907-z
    [38] Y. Shan, Q. Huang, D. Guan, K. Hubacek, China CO2 emission accounts 2016–2017, Sci. Data, 7 (2020), 54. https://doi.org/10.1038/s41597-020-0393-y doi: 10.1038/s41597-020-0393-y
    [39] Y. Shan, D. Guan, H. Zheng, J. Ou, Y. Li, J. Meng, et al., China CO2 emission accounts 1997–2015, Sci. Data, 5 (2018), 170201. https://doi.org/10.1038/sdata.2017.201 doi: 10.1038/sdata.2017.201
    [40] Shaanxi Provincial People's Government, Shaanxi Province " 14th Five-Year Plan" comprehensive work implementation plan for energy conservation and emission reduction, 2022. Available from: http://www.Shaanxi.gov.cn/zfxxgk/fdzdgknr/zcwj/nszfwj/szf/202302/t20230208_2274203.html
    [41] Shaanxi Provincial People's Government, Shaanxi Province industrial carbon peak implementation plan, 2023. Available from: https://www.miit.gov.cn/jgsj/jns/dfdt/art/2023/art_77ae4f2a46414393815d31cab6bb2b8d.html
    [42] Shaanxi Provincial Development and Reform Commission, The 14th Five-Year Plan for the National economic and Social Development of Shaanxi Province and the outline of the long-term goals for 2035, 2021. Available from: http://www.Shaanxi.gov.cn/xw/sxyw/202103/t20210302_2154680.html
    [43] State Council of PRC, National Population Development Plan (2016-2030), 2017. Available from: https://www.gov.cn/gongbao/content/2017/content_5171324.htm
    [44] Shaanxi Provincial People's Government, Shaanxi Provincial Population Development Plan (2016–2030), 2017. Available from: http://www.Shaanxi.gov.cn/zfxxgk/zfgb/2018_3966/d5q_3971/201803/t20180320_1638241_wap.html
    [45] J. J. Tian, X. Q. Song, J. S. Zhang, Prediction on carbon emission peak for typical coal-rich regions in Midwest China, Fresen. Environ. Bull., 31 (2022), 469–479.
    [46] K. Cai, L. F. Wu, Using grey Gompertz model to explore the carbon emission and its peak in 16 provinces of China, Energy Build., 277 (2022). https://doi.org/10.1016/j.enbuild.2022.112545 doi: 10.1016/j.enbuild.2022.112545
    [47] Y. Wu, B. Xu, When will China's carbon emissions peak? Evidence from judgment criteria and emissions reduction paths, Energy Rep., 8 (2022), 8722–8735. https://doi.org/10.1016/j.egyr.2022.06.069 doi: 10.1016/j.egyr.2022.06.069
    [48] C. F. Xu, Y. Zhang, Y. M. A. Yang, H. Y. Gao, Carbon peak scenario simulation of manufacturing carbon emissions in Northeast China: Perspective of structure optimization, Energies, 16 (2023). https://doi.org/10.3390/en16135227 doi: 10.3390/en16135227
    [49] L. L. Sun, H. J. Cui, Q. S. Ge, Will China achieve its 2060 carbon neutral commitment from the provincial perspective?, Adv. Climate Change Res., 13 (2022), 169–178. https://doi.org/10.1016/j.accre.2022.02.002 doi: 10.1016/j.accre.2022.02.002
  • Reader Comments
  • © 2023 the Author(s), licensee AIMS Press. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0)
通讯作者: 陈斌, bchen63@163.com
  • 1. 

    沈阳化工大学材料科学与工程学院 沈阳 110142

  1. 本站搜索
  2. 百度学术搜索
  3. 万方数据库搜索
  4. CNKI搜索

Metrics

Article views(1941) PDF downloads(60) Cited by(3)

Figures and Tables

Figures(9)  /  Tables(3)

Other Articles By Authors

/

DownLoad:  Full-Size Img  PowerPoint
Return
Return

Catalog